Pacific Biosciences of California Inc. will get $35 million upfront and possibly $40 million more in a deal to make diagnostic products with Roche Diagnostics. Menlo Park-based Pacific Biosciences (NASDAQ: PACB) will develop sequencing systems and consumable products under the deal, and will sell them exclusively to Roche, which has paid for an exclusive license to use the products for nucleic acid sequencing in human in vitro diagnostics. Pacific Biosciences will keep selling its products in other fields.
Help employers find you! Check out all the jobs and post your resume.
